Experimental Therapeutics Laboratory
The
Experimental Therapeutics Laboratory is a collaborative venture of the
Hanson Institute between scientists from the Cancer Clinical Trials Unit
(Royal Adelaide Hospital Cancer Centre), the Centre for Translational
Research (University
of Adelaide), and the Sansom
Institute (University
of South Australia).
We perform basic, translational and clinical research that aims to improve
cancer diagnosis and treatment. We are expert at exploiting the specificity
and power of the immune system to help us design, develop, and implement
cutting edge approaches to new cancer diagnostic and therapeutic agents.
Our industry links and experience and our clinical expertise together ensure
that our research has a strong likelihood of generating potentially
commercialisable applications and improved therapeutic outcomes for cancer
patients.
People
Co-laboratory heads
Professor Michael Brown
Dr John Hayball
Scientific staff
Dr Kerrilyn Diener
Dr Chris Della Vedova
Dr Erin Lousberg
Dr Cara Fraser
Dr Alex Staudacher
Support staff
Swati Irani
Research students
Susan Christo (PhD Student)
Stefani Griesser (PhD Student)
Stephanie Kershaw (PhD Student)
Jackson Ryan (Hons Student)
Natalie Stevens (Hons Student)
Crystal Khu (Hons Student)
Alan Dohnalek (Hons Student)
List of
Awards/Honours received by laboratory members (2010-2011)
Erin Lousberg:
Travel Scholarship to attend DC2010, International Society for Dendritic
Cell and Vaccine Science (2010); HDR International Travel Scholarship to
attend DC2010 (Sansom Institute, University of South Australia, 2010); Best
Oral Presentation by a PhD Student at the Adelaide Immunology Retreat
(AIR-6) (Australasian Society for Immunology, SA Branch, 2010)
Susan Christo
(PhD Student): Australiasian Society for Immunology SA/NT Annual Student
Retreat 6 Prize for Most Outstanding Presentation by an Honours/Masters
Student (2010); University of South Australia Honours Medal (2011);
University of South Australia PhD Top Up Scholarship; Royal Adelaide
Hospital DAWES Top Up Scholarship; Honours Scholarships for the Division of
Health Sciences, UniSA (2010); UniSA High Achiever Summer Scholarship – Top
Up (2010); Cancer Council SA Vacation Scholarship (2010)
Natalie Stevens
(Hons Student):
Royal Adelaide Hospital Research Committee Honours Scholarship (2011)
Alan Dohnalek
(Hons Student):
Royal Adelaide Hospital Research Committee Honours Scholarship (2011)
Successful grant applications
NHMRC Training Fellowship, Application ID 1012386.
‘Innate anti-viral effector responses and adverse reproductive
outcomes’. K.R.Diener. Awarded $290,032 for 2011-2014
NHMRC project grant “CARPETS: A Phase I Open Label Study of the
Safety and Immune effects of an Escalating Dose of Autologous GD2 Chimeric
Antigen Receptor-Expressing Peripheral Blood T Cells in Patients with
Metastatic BRAF-Mutant and GD2-Positive Melanoma”. MP Brown, I Lewis, CM
Bollard, MK Brenner, JD Hayball. Awarded $338,459.60 for 2011-2013
NHMRC Equipment Grant, Applications ID GNT9000031. ‘Becton Dickinson
FACSCanto II Three Colour Flow Cytometer’. W.V.Ingman, S.A.Robertson,
R.J.Rodgers, D.L.Russell, M.Lane, V.L.Clifton, M.L.Hull, M.R.Hutchinson, and
K.R.Diener. Awarded $90,000 for 2011
NHMRC Project ‘Chemokine gradients for directed migration of captured
cells and guidance of tissue engineering’. HJ Griesser, RD Short, K Vasilev,
MP Brown, JD Hayball, C McFarland. Awarded $228,750 p.a. for 2010-2012
NHMRC Program Grant ID453556. ‘Periconceptual foundations for a
healthy start to life’. R. J. Norman, R. J. Rodgers, S. A. Robertson, J. G.
Thompson, M. Lane, M. J. Davies, G. A. Dekker, H. F. Irving-Rodgers, M. J.
Jasper, J. D. Hayball, R. B. Gilchrist, K. L. Kind, V. M. Moore, K. Willson
and A. Chan. Awarded $180,000 2007-2011
NHMRC Project ID511303. ‘Immunotargeted nanoparticles to improve
tumour delivery of chemosensitising cytotoxic drugs and
b-radiation’.
HJ Griesser, BJ Thierry, MP Brown, P Majewski, J Taylor. Awarded $520,000
for 2008-2011
ARC Discovery Project ‘Advanced nanostructured biointerfaces for cell
capture’. HJ Griesser, CA
Prestidge, B Thierry, MP Brown, M Tabrizian. $150,000 p.a for 2008-2011.
RISS Ltd Researcher Access Program. “CARPETS: A Phase I Open Label
Study of the Safety and Immune effects of an Escalating Dose of Autologous
GD2 Chimeric Antigen Receptor-Expressing Peripheral Blood T Cells in
Patients with Metastatic BRAF-Mutant and GD2-Positive Melanoma”. MP Brown, I
Lewis, CM Bollard, MK Brenner. Awarded $100,000 for 2011-2013.
Australian New Zealand Melanoma Trials Group. ‘CARPETS: A Phase I
Open Label Study of the Safety and Immune effects of an Escalating Dose of
Autologous GD2 Chimeric Antigen Receptor-Expressing Peripheral Blood T Cells
in Patients with Metastatic BRAF-Mutant and GD2-Positive Melanoma’. M.P.
Brown. Awarded $28,000 for 2011
CRC for Wound Management and Innovation. ‘Novel bioactives for wound
repair’. H. Griesser, D. Steele, K. Vasilev and J. D. Hayball. Awarded
$75,000 for 2011-13
Royal Adelaide
Hospital Research
Committee Mary Overton Early Career Research Fellowship. ‘A comparative
analysis of the relative therapeutic efficacy of phenotypically-distinct
populations of genetically-modified tumour-specific T cells as detected and
assessed by functionalised solid support surfaces’. K.R.Diener. Awarded
$252,000 for 2011-2013. (Note: declined due to acceptance of NHMRC Training
Fellowship)
Royal Adelaide
Hospital Research
Committee Project Grant. ‘Assessing the neutralising activity of
therapeutic antibodies directed against the endogenous alarmin HMGB1 in
serum samples from septic shock patients and in an experimental murine model
of bacterial sepsis’. K.R.Diener M. Chapman and J.D. Hayball. Awarded
$25,000 for 2011
Royal Adelaide Hospital Clinical Project Grant, ‘Developing a
Rapid Whole Blood Assay for Estimating Immune Responses to Melanoma-directed
Immunotherapy’. CK Fraser, MP Brown, JD Hayball. Awarded $25,000 for
2011
University of
South Australia Competitive Research and
Development Award Scheme. ‘Research Support for Ms Erin Lousberg’. E. L.
Lousberg. Awarded $5,000 for 2011
BioinnovationSA Business Development Grant. ‘A preclinical evaluation
of the radioimmunotherapeutic application of APOMAB® in conjunction with
ionizing radiation’. Awarded to Medvet Pty Ltd.
M.P. Brown. Awarded $50,000 for 2011
Novartis Pharmaceuticals. ‘A Parallel Phase I Study of LBH589 in
Combination with External Beam Radiotherapy or Chemoradiation for Locally
Advanced Non Small Cell Lung Cancer’. N. Singhal and M.P. Brown. Awarded
$255,250 for 2008-2011
Enterprise
Connect ‘Researchers-in-Business’ Scheme Commercial Partners: BTG
Australasia Pty Ltd and UniSA. ‘Improving vaccination responses in sheep.’
J. D. Hayball and K. Sproston. Awarded $150,000 for 2010-2011
Current research activities
Melanoma research
projects:
The overall aim of these projects is to translate laboratory
advances in melanoma research to improved clinical outcomes for patients
with advanced melanoma. Some of the technologies being developed in
non-melanoma projects in our laboratory may produce an original solution to
the problem of detecting the function of genetically engineered T cells in
the blood of treated melanoma patients.
CARPETS: A Phase I Open Label Study of the Safety and Immune
effects of an Escalating Dose of Autologous GD2 Chimeric Antigen
Receptor-Expressing Peripheral Blood T Cells in Patients with Metastatic
BRAF-Mutant and GD2-Positive Melanoma
Malignant melanoma is increasing in incidence in
Australia. Once the disease has reached an
advanced stage the prognosis is poor, and the treatment options few. A new
drug, called a B-Raf inhibitor, targets a signalling pathway involved in
promoting melanoma growth. While this drug has therapeutic effects in a
large proportion of patient’s, disease control is short lived as resistance
to the drug inevitably develops. Prof Brown will lead a clinical trial
investigating the use of adoptive T cell immunotherapy to target melanoma
cells that have become resistant to B-Raf inhibitor treatment. This will
involve the genetic modification of the patients own T cells to redirect
them against the melanoma; these anti-melanoma T cells will then be
reinfused into the patient. The feasibility, safety and immune effects of
this therapy will be evaluated in patients who have advanced melanoma that
is no longer responsive to B-Raf inhibition.
A combinatorial approach to melanoma therapy: preclinical
evaluation of concurrent B-Raf inhibition and adoptive T cell immunotherapy
This preclinical study complements the CARPETS clinical trial and
investigates whether concurrent treatment with a B-Raf inhibitor and
genetically modified anti-melanoma T cells is feasible. We will evaluate the
effect of B-Raf inhibitor on the function of the genetically modified T
cells in vitro and the efficacy of combined treatment in vivo
in preclinical models of melanoma. It is hoped that this study will provide
justification for a future clinical trial combining these therapies.
Developing a Rapid Whole Blood Assay for Estimating Immune
Responses to Melanoma-directed Immunotherapy
We aim to develop a whole-blood immunoassay for the detection,
quantification, and monitoring of tumour antigen-specific T-cell responses
that is simpler and quicker to perform than currently used methods.
Novel cancer targeting research projects:
These projects will build on previous published work from our
laboratory and extend the application of this unique technology to a broader
range of human cancers.
APOMAB®
targeting of dead cancer cells for monitoring of cancer therapy
APOMAB® is a monoclonal antibody that binds to a protein that is
revealed during cell death. This technology aims to serve an unmet medical
need by determining whether a patient’s cancer responds to anti-cancer
treatment through the detection of cancer cell death soon after the
commencement of treatment. Then, doctors would continue useful treatment and
cease useless treatment, thus sparing the patient unnecessary toxicity. We
have established that APOMAB®
preferentially detects cancers at a late stage of cell death, which is
likely to be the stage that is most useful for the clinical application of
this technology. Plans are underway to make a clinical-grade APOMAB®
product for testing in a first-time-in-human clinical trial.
APOMAB®
targeting of dead cancer cells for delivery of cancer therapy
Since APOMAB®
can target dead cancer cells, which are created in response to chemotherapy
and which lie close to live cancer cells, we reasoned that the APOMAB® antibody could also be used to deliver an anti-cancer
treatment such as radioactivity, which can then kill the surrounding live
cancer cells. We have proven the case in preclinical cancer models and now
wish to show if a more powerful, targeted form of radioactivity in the form
of alpha-particles has superior therapeutic effects in the same preclinical
cancer models. We believe that this approach may improve anti-cancer
treatment without inducing any more damage to normal tissues.
Cancer vaccine research projects:
In these projects, we aim to study fundamental aspects of innate immune
function in order to understand how to improve the workings of cancer
vaccines.
Using recombinant fowlpox virus vectors in the development of cancer
vaccines
About 20% of human cancers originate after an initial infection such as
human papilloma virus (HPV or wart virus) that can cause cancer of the
uterine cervix. As the HPV vaccination program has already shown, if these
cancer-inducing infections can be eliminated then the subsequent cancers
themselves may be prevented. We are developing a platform vaccine vector
technology, which could be applied to a number of different types of
infections as well to some cases cancer directly and which thus could be
used both to treat and prevent these conditions. Although this promising
vaccine technology is being tested in current clinical trials for a number
of diseases such as HIV, melanoma and prostate cancer, an understanding of
how exactly it works is lacking. With an in-depth understanding of the
mechanisms underlying the action of this vaccine, we are now in a stronger
position to modify these vaccines in order to generate better immune
responses, which may translate to improved clinical benefits for patients.
Development of
microfluidics chips to isolate and analyse peripheral blood cell populations
in pancreatic cancer patients
Patients with
pancreatic cancer are frequently diagnosed at a late stage of the disease.
Making a diagnosis is often difficult due to limitations in obtaining cancer
tissue. Working in collaboration with experts in surface technology from the
Ian Wark Research Institute (University of South Australia) this project
aims to develop a microfluidics chip (‘lab on a chip’) that can be used to
obtain the rare circulating cancer cells directly from the blood of cancer
patients. Such a device would make cancer diagnosis easier, and guide the
earlier and more appropriate selection of anti-cancer treatment options.
Development of
a novel functionalised solid support surface for the detection and analysis
of antigen-specific T cells
Any worthwhile vaccine results in the body producing new T cells that
are available to fight an ensuing infection or an emerging cancer. The
vaccine contains an antigen that is specifically recognised by the new T
cells. However, identifying and analysing the properties of these
antigen-specific T cells in human blood after vaccination has not been easy
task. We are working on methods to improve this task. Consequently, we are
developing a device that enables the capture and functional analysis of
antigen-specific T cells that can later be applied to the study of blood
from vaccinated human subjects. Again in collaboration with the
Ian Wark Research
Institute, we are using specialised solid surfaces to investigate the
conditions required to capture and stimulate antigen specific T cells. We
anticipate that this technology will also be applied to studying the
function of genetically engineered T cells given to advanced melanoma
patients.
Targeting cancer cells through vaccination
The surface of cancer cells has increased numbers of some
signalling molecules when compared to normal surrounding cells. We have
decided to see whether we can use this information in the form of two
different kinds of vaccine, one virally based, to ‘teach’ the immune system
to attack cells based on the expression of these distinct molecules. If
successful, the development of such a vaccine would enable us to treat and
prevent cancers that express these cancer-specific molecules without harming
surrounding, normal tissues.
Cancer-related inflammation research
projects:
Inflammation can help to promote cancer or be manipulated to turn the cancer
against itself. The overall aim of these studies is to understand the role
of an important protein called HMGB1 in sepsis and cancer. A better
understanding of its role will enable more precise application of a new kind
of antibody that can neutralise activity of HMGB1.
Assessing the neutralising activity of anti-HMGB1 antibodies in serum
samples from septic shock patients and in an experimental murine model of
bacterial sepsis
Sepsis (or overwhelming infection) often causes death in the intensive
care unit and may complicate common anti-cancer treatments such as
chemotherapy. HMGB1 is secreted during serious infection and can mediate its
harmful effects. Blocking HMGB1 activity with antibody can prevent this
happening in animal models. Working with BTG Australasia, we propose to
develop neutralising antibodies against HMGB1 that could ameliorate clinical
course of sepsis in the hospital.
Assessing the neutralising activity of anti-HMGB1 antibodies in vitro and
in preclinical models of cancer
HMGB1 can be secreted by dead and dying cancer cells and push cancer
cells toward a type of cell death called autophagy, which can promote
resistance to commonly used anti-cancer agents. Blocking HMGB1 activity with
antibody may overcome the development of autophagy and help anti-cancer
drugs work better to kill cancer cells.
Ian Wark Research
Institute (University of South Australia)
Robinson Institute, University of Adelaide
Department of Medical Physics, Royal Adelaide Hospital Cancer Centre
Cancer Imaging Centre, Peter MacCallum Cancer Centre
Cell and Gene Therapy Center, Baylor College of Medicine, Houston TX, USA
Cancer and Vascular Biology Laboratory, John Curtin School of Medicine,
Australian National University
Medvet Pty Ltd
BTG Australasia Pty Ltd
ConCA Pty Ltd
Wu Y, Lousberg EL, Moldenhauer
LM, Hayball JD, Robertson SA, Coller JK, Watkins LR, Somogyi AA, Hutchinson
MR, Attenuation of microglial and IL-1 signaling protects mice from acute
alcohol-induced sedation and/or motor impairment, Brain Behavior and
Immunity, Jan 27, [Epub ahead of print], (2011)
Guerin LR, Moldenhauer LM, Prins JR, Bromfield JJ, Hayball JD,
Robertson SA, Seminal fluid regulates accumulation of FOXP3+ regulatory T
cells in the preimplantation mouse uterus through expanding the FOXP3+ cell
pool and CCL19-mediated recruitment, Biology of Reproduction, Mar 9,
[Epub ahead of print], (2011)
Barrios CH, Hernandez-Barajas D, Brown MP, Lee S-H, Fein L, Liu JH,
Hariharan S, Martell B, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY. Phase
II trial of continuous once-daily dosing of sunitinib as first-line
treatment in patients with metastatic renal cell carcinoma. Cancer
(Accepted 07 April 2011)
Kirkwood JM, Gonzalez R, Reintgen D, Clingan PR, McWilliams RR, de Alwis DP,
Zimmermann A, Brown MP, Ilaria RL Jr, Millward MJ, A phase 2 study of
tasisulam sodium (LY573636 sodium) as second-line treatment for patients
with unresectable or metastatic melanoma, Cancer, Mar 31, [Epub ahead
of print], (2011)
Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, López JA, Lakhani SR,
Brown MP, Khanna KK, Breast cancer stem cells: treatment resistance and
therapeutic opportunities, Carcinogenesis, Feb 10, [Epub ahead of
print], (2011)
Al-Ejeh F, Brown MP. Chapter 16: “Combined Modality Therapy:
Relevance for Targeted Radionuclide Therapy”, pages 220-235. In Targeted
Radionuclide Therapy. Ed., Tod W. Speer. Lippincott, Williams & Wilkinson,
Philadelphia, 2011
Brown MP. Do human lymphocyte antigens (HLA) play a role in the
clinical antimelanoma activity of ipilimumab? Immunotherapy (Accepted
07 February 2011)
Lousberg EL, Diener KR, Fraser CK, Phipps S, Foster PS, Chen W, Uematsu S,
Akira S, Robertson SA, Brown MP, Hayball JD. Antigen-specific T-cell
responses to a recombinant fowlpox virus are dependent on MyD88 and
interleukin-18 and independent of toll-like receptor 7 (TLR7)- and
TLR9-mediated innate immune recognition, Journal of Virology,
85(7):3385-96, (2011)
Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP, Callen DF,
Neilsen PM, Nutlin-3a is a potential therapeutic for ewing sarcoma,
Clinical Cancer Research, 17(3):494-504, (2011)
Moldenhauer LM, Hayball JD, Robertson SA, Utilising T cell receptor
transgenic mice to define mechanisms of maternal T cell tolerance in
pregnancy, Journal of Reproductive Immunology, 87(1-2):1-13, (2010)
Moldenhauer LM, Keenihan SN, Hayball JD, Robertson SA, GM-CSF is an
essential regulator of T cell activation competence in uterine dendritic
cells during early pregnancy in mice, Journal of Immunology,
185(11):7085-96, (2010)
Fraser CK, Diener KR, Lousberg EL, Both GW, Ward L, Brown MP, Hayball JD,
Induction of both cellular and humoral immunity following a rational
prime-boost immunization regimen that incorporates recombinant ovine
atadenovirus and fowlpox virus, Clinical and Vaccine Immunology,
17(11):1679-86, (2010)
Fraser CK, Lousberg EL, Guerin LR, Hughes TP, Brown MP, Diener KR, Hayball
JD, Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo,
Cancer Biology and Therapy, 10(7):715-27, (2010)
Diener KR, Need EF, Buchanan G, Hayball JD, TGF-beta signalling and immunity
in prostate tumourigenesis. Expert Opinion on Therapeutic Targets,
14(2):179-92, (2010)
Fraser CK, Brown MP, Diener KR, Hayball JD, Unravelling the complexity of
cancer-immune system interplay. Expert Reviews in Anticancer Therapy,
10(6):917-34, (2010)
Fraser CK, Diener KR,
Lousberg EL, Both GW, Ward L, Brown
MP, Hayball JD. Inducing both cellular and
humoral immunity following a rational prime-boost immunisation regimen
incorporating recombinant ovine atadenovirus and fowlpox virus. Clin
Vaccine Immunol 17:1679-1686, (2010)
Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, Khanna KK. Harnessing
the complexity of DNA-damage response pathways to improve cancer treatment
outcomes. Oncogene 29:6085-6098, (2010)
Al-Ejeh F, Darby JM, Thierry B, Brown MP, A simplified suite of methods to
evaluate chelator conjugation of antibodies: effects on hydrodynamic radius
and biodistribution, Nuclear Medicine and Biology, 36:395-402,
(2009)
Robertson SA, Guerin LR, Moldenhauer LM, Hayball JD, Activating T regulatory
cells for tolerance in early pregnancy - the contribution of seminal fluid,
Journal of Reproductive Immunology, 83:109-116, (2009)
Al-Ejeh F, Darby JM, Tsopelas C, Smyth D, Manavis J, Brown MP, APOMAB(R), a
La-specific monoclonal antibody, detects the apoptotic tumor response to
life-prolonging and DNA-damaging chemotherapy, PLoS ONE, 4:e4558,
(2009)
Al-Ejeh F, Darby JM, Brown MP, Chemotherapy synergizes with
radioimmunotherapy targeting la autoantigen in tumors, PLoS ONE,
4:e4630, (2009)
Moldenhauer LM, Diener KR, Thring DM, Brown MP, Hayball JD, Robertson SA,
Cross-presentation of male seminal fluid antigens elicits T cell activation
to initiate the female immune response to pregnancy, Journal of
Immunology, 182:8080-8093, (2009)
Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD,
Dasatinib inhibits recombinant viral antigen-specific murine CD4(+) and
CD8(+) T-cell responses and NK-cell cytolytic activity in vitro and in vivo,
Experimental Hematology, 37:256-265, (2009)
Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener KR, Hayball JD, Dasatinib
inhibits the secretion of TNF-a following TLR stimulation in vitro and in
vivo, Experimental Hematology, 37:1435-1444, (2009)
Thierry B, Al-Ejeh F, Khatri A, Yuan Z, Russell PJ, Ping S, Brown MP,
Majewski P, Multifunctional core-shell magnetic cisplatin nanocarriers,
Chemical Communications, 47:7348-7350, (2009)
Thierry B, Al-Ejeh F, Brown MP, Majewski P, Griesser HJ.
Immunotargeting of Advanced Functional Nanostructures for MRI detection of
Apoptotic Tumor Cells Adv Mater 21:541-545, (2009)
Diener KR, Woods AE, Manavis J, Brown MP, Hayball JD, Transforming growth
factor-beta-mediated signaling in T lymphocytes impacts on prostate-specific
immunity and early prostate tumor progression, Laboratory Investigation,
89:142-151, (2009)
Blake SJ, Lyons AB, Fraser CK, Hayball JD, Hughes TP., Dasatinib suppresses
in vitro natural killer cell cytotoxicity., Blood, 111:4415-4416,
(2008)
Philpott H, Hissaria P, Warrren L, Singhal N, Brown M, Proudman S, Cleland
L, Gillis D, Eosinophilic fasciitis as a paraneoplastic phenomenon
associated with metastatic colorectal carcinoma., Australasian Journal
of Dermatology (The), 49:27-29, (2008)
Luke C, Koczwara B, Karapetis C, Pittman K, Price T, Kotasek D, Beckmann K,
Brown MP, Roder D, Exploring the epidemiological characteristics of cancers
of unknown primary site in an Australian population: implications for
research and clinical care, Australian and New Zealand Journal of Public
Health, 32:383-389, (2008)
Diener KR, Moldenhauer LM, Lyons AB, Brown MP, Hayball JD, Human Flt-3
ligand-mobilized dendritic cells require additional activation to drive
effective immune responses., Experimental Hematology, 36:51-60,
(2008)
Diener KR, Lousberg EL, Beukema EL, Yu A, Howley PM, Brown MP, Hayball JD,
Recombinant fowlpox virus elicits transient cytotoxic T cell responses due
to suboptimal innate recognition and recruitment of T cell help. ,
Vaccine, 26:3566-3573, (2008)
Brown MP, Buckley MF, Rudzki B, Olver IN, Why we will need to learn new
skills to control cancer., Internal Medicine Journal, 37:201-204,
(2007)
Singhal N, Selva-Nagayam S, Brown MP. Prolonged
and severe myelosuppression in two patients after low-dose temozolomide
treatment - case study and review of literature. J Neuro-oncol
85:229-230, (2007)
Al-Ejeh F, Darby JM, Brown MP. The La autoantigen is a malignancy-associated
cell death target that is induced by DNA-damaging drugs. Clin Cancer Res
13:5509s-5518s, (2007)
Al-Ejeh F, Darby JM, Pensa K, Diener KR, Hayball JD, Brown
MP. In vivo targeting of dead tumor cells in a murine tumor
model using a monoclonal antibody specific for the La autoantigen. Clin
Cancer Res 13:5519s-5527s, (2007)
Moldenhauer LM, Hayball JD, Robertson SA, Conceptus antigens activate the
maternal immune response in pregnancy utilising maternal antigen presenting
cells., Journal of Reproductive Immunology, 71(2):148-148, (2006)
Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Zhuyong M, Grilley
B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrun G, Margolin JF,
Brenner MK, Immunotherapy of high-risk acute leukemia with a recipient (autologous)
vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and
allogeneic stem cell transplantation., Blood, 107:1332-1341, (2006)
Lees JR, Charbonneau B, Hayball JD, Diener K, Brown MP, Matusik R, Cohen MB,
Ratliff TL, T-cell recognition of a prostate specific antigen is not
sufficient to induce prostate tissue destruction., 66:578-590, (2006)
Beukema EL, Brown MP, Hayball JD. The potential role
of fowlpox virus in rational vaccine design. Expert Rev Vaccines
5:565-577, (2006)
Butler LM, Centenera MM, Neufing PJ, Buchanan G, Choong CS, Ricciardelli C,
Saint K, Lee MA, Ochnik A, Yang M, Brown MP, Tilley WD. Suppression of
androgen receptor signalling in prostate cancer cells by an inhibitory
receptor variant. Mol Endocrinol 20:1009-1024, (2006)
Fore more information on the Experimental Therapeutics Laboratory, please
contact Dr John Hayball on:
Phone: +61 8 8302 1202
Email: john.hayball@unisa.edu.au
top^
